All articles by Phillip Broadwith – Page 5
-
OpinionIs Bayer regretting its Monsanto takeover?
Large damages in Roundup litigation have got investors questioning the move
-
BusinessAt least six dead in explosions in US and Russia
Blasts at silicones and fertiliser plants each leave three confirmed dead
-
OpinionShow me the data
Making industrial safety research more transparent benefits both companies and consumers
-
BusinessDeadly explosion at US chemical plant
Isobutylene tank explosion kills one and hospitalises two at KMCO plant in Crosby
-
-
OpinionDivergent reality
If the UK leaves the EU without a deal, the two will inevitably drift further apart
-
BusinessWhat might Brexit mean for industry?
Questions hang over regulation, trade, talent and investment
-
OpinionThinking differently about waste
Plastic and carbon emissions are valuable resources we can’t afford to discard
-
-
ReviewOrganic Chemistry for Babies
A chance for parents to start training the next generation of chemists
-
OpinionPushing the limits of patent protection
Some methods of extending exclusivity rights raise legal and ethical questions
-
OpinionPassing through checkpoints
A new breed of cancer treatments highlights what’s possible when industry concentrates its efforts
-
OpinionHas Crispr’s patent battle run its course?
As the originators duke it out in court, their patents are becoming increasingly irrelevant
-
OpinionBehind enemy lines
When trade war breaks out, globalised industries ship out to dodge tariffs
-
BusinessCompany profile: Ellutia
Ellutia takes GC beyond the ‘box-in-the-lab’, with its customised chromatography
-
-
BusinessValeant relinquishes female libido drug
Struggling firm is returning Sprout Pharmaceuticals subsidiary to original shareholders to resolve dispute over marketing
-
BusinessGenerics firms Amneal and Impax to merge
Deal continues consolidation trend, based on portfolio expansion and simplifying supply chains
-
BusinessNovartis to buy AAA for radioligand cancer drugs
$3.9bn deal follows European approval of Advanced Accelerator Applications’ first-in-class radionuclide drug Lutathera
-
OpinionAre trade sanctions fair?
How much should markets be protected from cheaper imports? When does healthy competition become ‘dumping’?